Elapegademase

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.[1]

Elapegademase
Clinical data
Trade namesRevcovi
Other nameselapegademase-lvlr
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intramuscular
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG

It is a recombinant enzyme[2] that is administered weekly by intramuscular injection.[3]

Elapegademase may interact with PEGylated drugs.[3]

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.[4][5][6] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[7]

References
  1. Skidmore-Roth L (2022). "Elapegademase". Mosby's 2023 Nursing Drug Reference. Elsevier Health Sciences. p. 429. ISBN 978-0-323-93330-8.
  2. "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
  3. "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
  4. "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Retrieved 26 December 2019.
  5. "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
  6. "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
  7. "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.
  • "Elapegademase". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.